Sector Expert: Rik Deitsch
Rik J. Deitsch, chairman and CEO of Nutra Pharma, holds a master's degree in biochemistry and a bachelor's degree in chemistry, and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is the author of two books and is an adjunct professor for Florida Atlantic University's College of Business and Continuing Education Department.
OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch (10/21/15)
A strategy of over-the-counter sales helps derisk Nutra Pharma Corp. as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates how he plans to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases.